2Seventy Bio Inc Asset Resilience Ratio
2Seventy Bio Inc asset resilience ratio. 2Seventy Bio Inc (TSVT) has an Asset Resilience Ratio of 16.25% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 2Seventy Bio Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of 2Seventy Bio Inc (2020–2024)
Asset resilience ratio of 2Seventy Bio Inc from 2020 to 2024. This chart shows how 2Seventy Bio Inc's Asset Resilience Ratio has changed over time. Read 2Seventy Bio Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down 2Seventy Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 2Seventy Bio Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $78.02 Million | 16.25% |
| Total Liquid Assets | $78.02 Million | 16.25% |
Asset Resilience Insights
- Good Liquidity Position: 2Seventy Bio Inc maintains a healthy 16.25% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
2Seventy Bio Inc Industry Peers by Asset Resilience Ratio
Compare 2Seventy Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE |
Biotechnology | 35.63% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 3.03% |
2Seventy Bio Inc Asset Resilience Ratio by Year (2020–2024)
2Seventy Bio Inc asset resilience ratio by year from 2020 to 2024. The table below shows the annual Asset Resilience Ratio data for 2Seventy Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 21.59% | $103.51 Million | $479.51 Million | -3.53pp |
| 2023-12-31 | 25.12% | $142.03 Million | $565.43 Million | -4.61pp |
| 2022-12-31 | 29.73% | $195.24 Million | $656.66 Million | +12.01pp |
| 2021-12-31 | 17.72% | $134.64 Million | $759.67 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $312.62 Million | -- |
About 2Seventy Bio Inc
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was inco… Read more